Imad Sheiban, ESC 2020 – Left Main Percutaneous Coronary Intervention Part 2
We spoke to Prof Imad Sheiban (Interventional Cardiology, P Pederzoli Hospital Peschiera del Garda, Verona, Italy) on the topic of left main angioplasty and percutaneous coronary intervention of the left main. Here, he answers our questions.
Part Two: Questions
- In which patients is percutaneous coronary intervention (PCI) of left main coronary stenosis a safe alternative to coronary artery bypass grafting? (0.06)
- What are the major risks involved in left main PCI and what can be done to minimise these risks? (1.30)
- What stenting techniques do you recommend to optimise outcomes in these patients? (3.48)
- What have been the most important advances in PCI in left main disease in recent years? (6.27)
- What are the take home messages of your presentation? (8.28)
Speaker disclosures: Professor Imad Sheiban has nothing to declare in relation to this video interview.
Support: Commissioned, edited and funded by Touch Medical Media.
Share this Video
Related Videos In Interventional Cardiology
Hyo-Soo Kim, ACC 2023: Guidelines for the use of short-term dual antiplatelet therapy after coronary intervention
The guidelines for the use of short-term dual antiplatelet therapy (DAPT) after coronary intervention vary depending on the patient’s clinical situation and the type of intervention performed. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) to discuss the current guidelines for the […]
Hyo-Soo Kim, ACC 2023: HOST IDEA trial – Short-term dual antiplatelet therapy non-inferior to 12 Months after PCI with third-generation drug-eluting stents
The goal of dual antiplatelet therapy (DAPT) is to reduce the risk of stent thrombosis, a potentially life-threatening complication that can occur when blood clots form in the stent. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) highlights the findings from the […]
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!